Informing Pharmaceutical Innovation Policy: The Health Value of R&D Cost Transparency
Good pharmaceutical innovation policy requires good data about R&D costs. By looking at the economics of the pharmaceutical R&D process, with the use of accurate data about costs, risks, and returns, policymakers can more accurately respond to competing claims for access and incentives to innovate and find ways of promoting affordable, accessible, and innovative drugs while discouraging redundant investments in high cost, low value added drugs. If our pharmaceutical innovation policy goal is truly to make positive contributions to public health, this kind of data should be readily available in usable forms for all drugs and should be used to inform public spending and the design of regulatory incentives.
Authors
- Liza Vertinsky (ORCID: https://orcid.org/0000-0002-7173-0882)
Institutions
- University of Maryland, Baltimore (US)
Publication Details
- Journal
- The Journal of Law Medicine & Ethics
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1017/jme.2026.10297
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00